FDA 483 - Rafa Laboratories Ltd.

An FDA inspection of Rafa Laboratories, Ltd. in Jerusalem, Israel, a sterile drug manufacturer, revealed significant deficiencies in aseptic processing controls. Observations included inadequate smoke studies, lack of visible particulate inspection, poor aseptic practices, and issues with cleaning agents, sampling procedures, and reference standard qualification.